3,468 Quest Diagnostics Incorporated $DGX Shares Bought by Simplicity Wealth LLC

Simplicity Wealth LLC increased its holdings in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 15.6% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 25,650 shares of the medical research company’s stock after acquiring an additional 3,468 shares during the period. Simplicity Wealth LLC’s holdings in Quest Diagnostics were worth $5,978,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in Quest Diagnostics during the second quarter worth about $1,965,923,000. EdgePoint Investment Group Inc. lifted its position in shares of Quest Diagnostics by 35.1% during the 1st quarter. EdgePoint Investment Group Inc. now owns 2,243,869 shares of the medical research company’s stock worth $439,753,000 after buying an additional 582,797 shares during the period. Bank of America Corp DE bought a new position in shares of Quest Diagnostics during the 2nd quarter worth approximately $410,151,000. Dimensional Fund Advisors LP lifted its position in shares of Quest Diagnostics by 0.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,949,535 shares of the medical research company’s stock worth $382,085,000 after buying an additional 17,987 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Quest Diagnostics by 11.3% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 942,407 shares of the medical research company’s stock valued at $199,743,000 after buying an additional 95,804 shares in the last quarter. Institutional investors and hedge funds own 88.06% of the company’s stock.

Key Quest Diagnostics News

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Third-quarter results beat estimates: Quest reported adjusted EPS of $3.00 versus the $2.87 consensus and revenue of $3.10 billion versus expectations of $3.05 billion. Revenue increased 10% year over year, while adjusted EPS rose 15.4%, reflecting stronger testing demand and margin improvement. Quest Diagnostics Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Full-year guidance was raised: Quest now expects 2026 revenue of $12.065 billion to $12.105 billion and adjusted EPS of $11.25 to $11.35, above consensus estimates of approximately $12.0 billion and $11.19, respectively. Organic requisition volume rose 14.4% in the quarter, and consumer-health revenue is expected to grow more than 30% for the year. Quest Diagnostics Earnings Takeaways
• Positive Sentiment: Valuation and momentum remain supportive: Coverage characterized DGX as potentially undervalued following the guidance increase, while Zacks highlighted the company’s long-term momentum profile. Quest Diagnostics Could Be Undervalued
• Neutral Sentiment: Deutsche Bank raised its price target to $245 from $232 but maintained a Hold rating, indicating improved expectations without a clear bullish endorsement. Deutsche Bank Adjusts Quest Diagnostics Price Target
• Negative Sentiment: Patient-data breach creates a major overhang: Quest disclosed unauthorized access to its Quanum Lab Services Manager, a system used to order tests and access results. The company confirmed that personal and health information was compromised, potentially exposing it to regulatory scrutiny, litigation, remediation costs, and reputational damage. Quest Diagnostics Patient Data Breach

Analyst Ratings Changes

A number of analysts have weighed in on DGX shares. Wall Street Zen upgraded Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 28th. Robert W. Baird set a $262.00 price objective on Quest Diagnostics in a research note on Friday. JPMorgan Chase & Co. lifted their price objective on Quest Diagnostics from $220.00 to $250.00 and gave the company a “neutral” rating in a report on Tuesday, July 28th. Barclays boosted their target price on shares of Quest Diagnostics from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Finally, Truist Financial upped their target price on shares of Quest Diagnostics from $250.00 to $260.00 and gave the stock a “hold” rating in a report on Monday, September 21st. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Quest Diagnostics currently has an average rating of “Moderate Buy” and a consensus target price of $244.27.

Quest Diagnostics Stock Performance

NYSE DGX opened at $241.49 on Friday. Quest Diagnostics Incorporated has a 1-year low of $171.18 and a 1-year high of $248.84. The company has a 50 day moving average of $237.67 and a 200-day moving average of $216.82. The company has a current ratio of 1.70, a quick ratio of 1.46 and a debt-to-equity ratio of 0.70. The firm has a market cap of $26.65 billion, a price-to-earnings ratio of 24.05, a PEG ratio of 2.17 and a beta of 0.54.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Thursday, October 22nd. The medical research company reported $3.00 EPS for the quarter, topping the consensus estimate of $2.87 by $0.13. The business had revenue of $3.10 billion for the quarter, compared to the consensus estimate of $3.05 billion. Quest Diagnostics had a return on equity of 16.21% and a net margin of 9.53%. Quest Diagnostics’s revenue was up 10.0% compared to the same quarter last year. During the same period in the previous year, the business earned $2.60 EPS. On average, equities analysts forecast that Quest Diagnostics Incorporated will post 11.27 earnings per share for the current fiscal year.

Quest Diagnostics Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, October 21st. Investors of record on Tuesday, October 6th were issued a dividend of $0.86 per share. This represents a $3.44 dividend on an annualized basis and a yield of 1.4%. The ex-dividend date of this dividend was Tuesday, October 6th. Quest Diagnostics’s dividend payout ratio (DPR) is currently 34.26%.

Insider Buying and Selling at Quest Diagnostics

In other news, CEO J. E. Davis sold 10,000 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $242.72, for a total transaction of $2,427,200.00. Following the sale, the chief executive officer owned 122,423 shares in the company, valued at approximately $29,714,510.56. This represents a 7.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Mark E. Delaney sold 1,600 shares of the stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $235.18, for a total value of $376,288.00. Following the sale, the senior vice president owned 10,335 shares in the company, valued at $2,430,585.30. The trade was a 13.41% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 34,277 shares of company stock worth $8,316,493. 0.88% of the stock is currently owned by insiders.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated (NYSE: DGX) is a provider of diagnostic information services. The company performs laboratory testing that helps physicians, hospitals and other healthcare providers diagnose, treat and monitor diseases and health conditions. Its services include routine blood and other specimen testing, pathology, molecular and genetic testing, and specialized diagnostic services.

Quest Diagnostics serves a broad range of customers, including hospitals, physician practices, health plans, employers, government agencies and individual consumers.